Beschreibung
Michael D. Wendt ProteinProtein Interactions as Drug TargetsShaomeng Wang, Yujun Zhao, Denzil Bernard, Angelo Aguilar, Sanjeev Kumar Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics Kurt Deshayes, Jeremy Murray, Domagoj Vucic The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer John F. Kadow, David R. Langley, Nicholas A. Meanwell, Michael A. Walker, Kap-Sun Yeung, Richard Pracitto ProteinProtein Interaction Targets to Inhibit HIV1 Infection Nicholas A. Meanwell, David R. Langley Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion - a Focus on Respiratory Syncytial VirusAndrew B. Mahon, Stephen E. Miller, Stephen T. Joy, Paramjit S. Arora Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces Michael D. Wendt The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
Herstellerkennzeichnung:
Springer Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE
E-Mail: juergen.hartmann@springer.com
